Lung Adenocarcinoma Stage III
2 clinical trials · Condition
◉ Watch Lung Adenocarcinoma Stage III
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma (NCT05503667) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-02-01 |
| Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma (NCT04201756) | Shanghai Pulmonary Hospital, Shanghai, China | 2020-07-26 |
Track Lung Adenocarcinoma Stage III automatically
Every clearance here is in the API, with alerts when new ones post.